The predominant risk factor for the development of TdP is co-administration of other medications which are substrates and/or inhibitors of cytochrome P450 (CYP) enzymes, and the associated ‘metabolic liability’ resulting from co-administration of medications synergistically interacting with this enzyme. The gene discussed is PPIG; the disease is torsades de pointes.